TPO and autoimmune thrombocytopenic purpura: Fourteen patients (18%) received ≥2 concurrent ITP treatments, including TPO‐RAs and corticosteroids (n = 2); TPO‐RA and IVIg (n = 2); and combinations of mainly either TPO‐RA and/or corticosteroids with other ITP agents in one patient each.